Navigation Links
Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Date:9/21/2007

DANBURY, Conn., Sept. 21 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have been initiated in Germany and patient treatment has begun.

"We are expanding VIAject(TM)'s pivotal Phase III trials into Europe to support our planned European registration of VIAject(TM)," stated Dr. Solomon S. Steiner, Chairman and CEO of Biodel. "Given the worldwide prevalence of diabetes, we are determined to establish VIAject(TM) as a global solution. Evaluating VIAject(TM)'s therapeutic profile in European patients with Type 1 and Type 2 diabetes gives us the opportunity to demonstrate VIAject(TM)'s clinical outcomes across a more diverse patient population."

VIAject(TM) is currently undergoing two pivotal Phase III clinical studies. The two studies, one enrolling 400 Type 1 diabetic patients and the other enrolling 400 Type 2 diabetic patients, are comparing the effects of VIAject(TM) to Humulin(R) R, the leading recombinant human insulin. Both studies are open label and involve a treatment regimen that is six months in duration. Clinical endpoints of both trials include non-inferiority in terms of HbA1c levels and safety.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and tw
'/>"/>

SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
2. PromegaExpress Expands Easy Access to Products with New Cabinet
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
6. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Yesterday, former Congressman ... device manufacturing facility. Rep. Kennedy and Dick ... facilitate cutting-edge research in neurological disease and treatment. ... health advocate, Garen Staglin , created One ... fundamental changes that will radically accelerate the development ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... LONDON, March 2, 2012  ConvaTec, a world-leading developer ... and hospital care today announced that Amcare Ltd, ... has acquired SureCalm Healthcare Holdings Ltd and subsidiaries ... specialises in the home delivery of prescribable stoma ...
... Mich., March 2, 2012 Rubicon Genomics, Inc., ... to improve the capabilities and performance of DNA ... has selected Velesco Pharmaceutical Services to manufacture the ... with Agendia,s breast cancer diagnostics.  Velesco is a ...
Cached Medicine Technology:ConvaTec Announces Acquisition of SureCalm Healthcare 2Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use 2Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use 3
(Date:7/12/2014)... (PRWEB) July 12, 2014 Restore My ... Sen and Samantha Pearson, a couple boasting very impressive ... launch Restore My Vision Today as a way to ... ophthalmologists have become in their respective patients’ treatments ... privy to a “secret” trove of pertinent information relevant ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/12/2014)... Ladies, it doesn't matter what your budget is, ... looking for an affordable gown can visit Discount-Dress.com ... get their dream items. Recently, the company has announced its ... Along with that, it is also providing great discounts for ... the deadline of this promotion is July 29, 2014. ...
(Date:7/11/2014)... Recently, DressyQuinceanera.com, a well-known wedding dress ... dresses to its online category. Furthermore, the firm ... deeply discounted rates, up to 62% off. , The ... excellent in terms of quality and style. All items ... are also offered for the company’s other items: lace ...
(Date:7/11/2014)... (PRWEB) July 12, 2014 According ... the total market is expected to register a ... 2019. , Browse 71 market data tables and ... TOC on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , ... report., http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides ...
Breaking Medicine News(10 mins):Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4
... (HCV) can be transmitted during intravenous (IV) administration of ... , the official journal of the American Gastroenterological Association ... contamination not endoscopy contamination was the cause ... educate the health-care community on the importance of strict ...
... July 22, 2010 (Oakland, Calif.) A total joint ... can enhance patient safety, quality of care, cost-effectiveness and ... and print editions of Clinical Orthopedics and Related ... and Joint Surgeons. Kaiser Permanente,s Total Joint ...
... circumcision has been proposed as a possible HIV prevention strategy ... University of Pittsburgh Graduate School of Public Health presented ... a very small effect on reducing HIV incidence in the ... risk of HIV transmission by removing cells in the foreskin ...
... Reporter , WEDNESDAY, July 21 (HealthDay News) -- Scientists believe ... they say could lead to the first drugs to tame ... are intolerant to the protein gluten, which is found in ... reaction that damages the lining of the small intestine, which ...
... University/University Hospitals Case Medical Center Center for AIDS ... five-year renewal grant from the National Institutes of ... clinical and technological support to researchers working on ... Case Medical Center, MetroHealth Medical Center, Cleveland Clinic, ...
... Reporter , WEDNESDAY, July 21 (HealthDay News) -- A two-step ... arteries and then inserts stem cells to promote healing of ... research suggests. "One of the problems of removing plaque ... damage to the underlying wall," explained Dr. Edward A. Fisher, ...
Cached Medicine News:Health News:Misuse of anesthesia could cause hepatitis virus transmission 2Health News:Kaiser Permanente demonstrates success of large-scale total joint replacement registry 2Health News:Study Points to Molecular Origins of Celiac Disease 2Health News:Study Points to Molecular Origins of Celiac Disease 3Health News:$9M NIH grant renewal awarded to Case Western Reserve/UHCMC Center for AIDS Research 2Health News:$9M NIH grant renewal awarded to Case Western Reserve/UHCMC Center for AIDS Research 3Health News:Procedure Rejuvenates Aging Arteries in Pigs 2Health News:Procedure Rejuvenates Aging Arteries in Pigs 3
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® Specialty Tubes - Other - Plastic...
BD Vacutainer® Specialty Tubes - Lead Testing...
Medicine Products: